Mannitol Injection, Solution
Product Images NDC 51662-1468

13 FDA label images from Hf Acquisition Co Llc, Dba Healthfirst · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Mannitol (NDC 51662-1468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse Reactions (Adverse Reactions)

Adverse Reactions (Adverse Reactions)
A table listing adverse reactions organized by system organ class for Mannitol injection, solution. Categories include renal and urinary disorders, CNS toxicity, metabolism and nutrition disorders, injection site reactions, cardiac disorders, vascular disorders, respiratory disorders, gastrointestinal disorders, eye disorders, musculoskeletal disorders, skin disorders, infections, and general disorders with related side effects noted.*
FDA Label Image

Description (Description)

Description (Description)
A data table showing concentration (%) of 25, grams per 100 mL as 25, calculated osmolarity as 1372 mOsmol/liter, and pH range from 4.5 to 7.0 with an average pH of 5.9, related to Mannitol injection solution.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of Mannitol showing its molecular arrangement with carbon (C), hydrogen (H), and hydroxyl (OH) groups clearly depicted in a linear format.*
FDA Label Image
FDA Label Image

Principal Display Panel (VIAL LABEL OPT. 1)

Principal Display Panel (VIAL LABEL OPT. 1)
Label for Mannitol 25% Injection, USP at 12.5 g/50 mL (250 mg/mL) in a 50 mL single-dose flipt-top vial. The label includes a warning about contraindication in severe renal impairment. It is for intravenous use only and manufactured by Hospira, Inc. The label also provides storage instructions and cautions for proper use.*
FDA Label Image

Principal Display Panel (VIAL LABEL OPT. 2)

Principal Display Panel (VIAL LABEL OPT. 2)
Label for Mannitol 25% Injection, USP, 12.5 g/50 mL (250 mg/mL) injection solution in a 50 mL single-dose fliptop vial. Distributed by Hospira, Inc. The label includes storage instructions, pH information, and warnings about contraindications in severe renal impairment. NDC 0409-4031-16 is shown.*
FDA Label Image

Principal Display Panel (VIAL LABEL OPT. 3)

Principal Display Panel (VIAL LABEL OPT. 3)
MANNITOL 25% Injection, USP 12.5 g/50 mL (250 mg/mL) intravenous solution in a 50 mL single-dose Fliptop vial. The label includes warnings about renal impairment and specifies Rx only. Distributed by Hospira, Inc., DBA HealthFirst, with National Drug Code 0409-4031-16.*
FDA Label Image

Principal Display Panel (VIAL LABEL OPT. 4)

Principal Display Panel (VIAL LABEL OPT. 4)
Label for MANNITOL Injection, USP 12.5 g/50 mL (25%), a single-dose fliptop vial for intravenous use. The label includes a warning about severe renal impairment contraindication. It states the product is Rx only, provides dosage details, storage instructions, and is labeled by Hospira, Inc., Lake Forest, IL.*
FDA Label Image

Principal Display Panel (SERIALIZED VIAL LABELING)

Principal Display Panel (SERIALIZED VIAL LABELING)
MANNITOL 12.5 g/50 mL (25%) injection solution in a 50 mL single-dose Fliptop vial. The label includes a barcode, manufacturer information as HF Acquisition Co LLC, and warnings related to contraindications in severe renal impairment. The vial has a yellow fliptop cap and is intended for intravenous use only.*
FDA Label Image

Pouch Labeling (Pouch Label)

Pouch Labeling (Pouch Label)
Label for Mannitol Injection, USP 12.5 g/50 mL (250 mg/mL) solution in a 50 mL vial. The label includes NDC 51662-1468-2, lot number, expiration date, usage instructions, storage conditions, manufacturer HF Acquisition Co., LLC, and a QR code. Intended for intravenous use only.*
FDA Label Image

Vial Label (Vial Label X)

Vial Label (Vial Label X)
Label for 25% Mannitol Injection, USP, 12.5 g/50 mL (250 mg/mL) single-dose fliptop vial for intravenous use. Contains warnings about contraindication in severe renal impairment. Distributed by Hospira, Inc., Lake Forest, IL. Includes NDC 0409-4031-16 and storage, administration, and caution information.*
FDA Label Image

Case Labeling (Case Label)

Case Labeling (Case Label)
Label for Mannitol Injection, USP 12.5 g/50 mL (250 mg/mL) in a 50 mL vial, packaged as a case. The label includes the NDC 51662-1468-3, lot number, expiration date, warnings, administration instructions, and manufacturer details (HF Acquisition Co LLC, DBA HealthFirst, Mukilteo, WA). It specifies intravenous use and storage instructions.*
FDA Label Image

Rfid Label (51662 1468 3 Rfid)

Rfid Label (51662 1468 3 Rfid)
Label for MANNITOL injection, solution, 12.5 g/50mL, for intravenous use. Label includes barcodes and numeric codes along with distributor information for HF Acquisitions Co., LLC, Mukilteo, WA. The label instructs to see manufacturer's insert for complete information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.